PET/CT Assessment of Estrogen Receptor positivity for Breast Cancer using [68Ga]Ga-RM2 Bombesin Receptor Antagonist: A Systematic Review and Meta-Analysis.

IF 4.6 2区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Akram Al-Ibraheem, Ahmed Saad Abdlkadir, Hongcheng Shi, Hikmat Abdel-Razeq, Asem Mansour
{"title":"PET/CT Assessment of Estrogen Receptor positivity for Breast Cancer using [<sup>68</sup>Ga]Ga-RM2 Bombesin Receptor Antagonist: A Systematic Review and Meta-Analysis.","authors":"Akram Al-Ibraheem, Ahmed Saad Abdlkadir, Hongcheng Shi, Hikmat Abdel-Razeq, Asem Mansour","doi":"10.1053/j.semnuclmed.2024.09.003","DOIUrl":null,"url":null,"abstract":"<p><p>[<sup>68</sup>Ga]Ga-RM2 is a novel gastrin-releasing peptide receptor antagonist with emerging diagnostic utility in low-grade breast cancer (BC) expressing estrogen receptors (ER). This systematic review and meta-analysis evaluates the current diagnostic utility of [<sup>68</sup>Ga]Ga-RM2 PET/CT and explores BC tumor uptake metrics in ER-positive BC lesions. A systematic search of PubMed, Scopus, and Web of Science databases was conducted using relevant keywords to extract, screen, and select eligible data for analysis. Out of 182 articles reviewed, only four studies were found eligible for inclusion. Qualitative data analysis was applied to four included papers meeting the eligibility criteria. Various promising utilities were identified, including [<sup>68</sup>Ga]Ga-RM2's ability to detect ER-positive primary BC lesions, lymph nodes, and distant metastatic lesions. Additionally, recent studies have addressed its potential for assessing therapy response following neoadjuvant chemotherapy. Importantly, [<sup>68</sup>Ga]Ga-RM2 has demonstrated clinical utility in improving and guiding proper management planning by detecting metastatic lesions that can alter overall staging and treatment strategies. The overall lesion detectability was 93% (95% CI: 87-98%) for ER-positive BC. ER-positive BC lesions showed significantly higher maximum standardized uptake values (SUVmax) compared to ER-negative lesions, with a weighted mean difference (WMD) of 10.6 (95% CI: 8.1-13.2; P < 0.00001). Furthermore, ER-positive BC lesions exhibited statistically significant higher SUVmax compared to normal background breast tissue SUVmean, with an overall WMD of 9.9 (95% CI: 7.5-12.2; P < 0.00001). Further studies utilizing this promising radiotracer should be encouraged, implementing prospective, large-scale designs in the near future.</p>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in nuclear medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1053/j.semnuclmed.2024.09.003","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

[68Ga]Ga-RM2 is a novel gastrin-releasing peptide receptor antagonist with emerging diagnostic utility in low-grade breast cancer (BC) expressing estrogen receptors (ER). This systematic review and meta-analysis evaluates the current diagnostic utility of [68Ga]Ga-RM2 PET/CT and explores BC tumor uptake metrics in ER-positive BC lesions. A systematic search of PubMed, Scopus, and Web of Science databases was conducted using relevant keywords to extract, screen, and select eligible data for analysis. Out of 182 articles reviewed, only four studies were found eligible for inclusion. Qualitative data analysis was applied to four included papers meeting the eligibility criteria. Various promising utilities were identified, including [68Ga]Ga-RM2's ability to detect ER-positive primary BC lesions, lymph nodes, and distant metastatic lesions. Additionally, recent studies have addressed its potential for assessing therapy response following neoadjuvant chemotherapy. Importantly, [68Ga]Ga-RM2 has demonstrated clinical utility in improving and guiding proper management planning by detecting metastatic lesions that can alter overall staging and treatment strategies. The overall lesion detectability was 93% (95% CI: 87-98%) for ER-positive BC. ER-positive BC lesions showed significantly higher maximum standardized uptake values (SUVmax) compared to ER-negative lesions, with a weighted mean difference (WMD) of 10.6 (95% CI: 8.1-13.2; P < 0.00001). Furthermore, ER-positive BC lesions exhibited statistically significant higher SUVmax compared to normal background breast tissue SUVmean, with an overall WMD of 9.9 (95% CI: 7.5-12.2; P < 0.00001). Further studies utilizing this promising radiotracer should be encouraged, implementing prospective, large-scale designs in the near future.

使用[68Ga]Ga-RM2蚕豆素受体拮抗剂评估乳腺癌雌激素受体阳性的 PET/CT:系统回顾与元分析》。
[68Ga]Ga-RM2是一种新型胃泌素释放肽受体拮抗剂,对表达雌激素受体(ER)的低级别乳腺癌(BC)有新的诊断作用。本系统综述和荟萃分析评估了[68Ga]Ga-RM2 PET/CT目前的诊断效用,并探讨了ER阳性BC病变的BC肿瘤摄取指标。该研究使用相关关键词对 PubMed、Scopus 和 Web of Science 数据库进行了系统检索,以提取、筛选和选择符合条件的数据进行分析。在查阅的 182 篇文章中,只有四项研究符合纳入条件。对符合资格标准的四篇纳入论文进行了定性数据分析。研究发现了多种有前景的实用方法,包括[68Ga]Ga-RM2检测ER阳性的原发性BC病灶、淋巴结和远处转移病灶的能力。此外,最近的研究还探讨了[68Ga]Ga-RM2在新辅助化疗后评估治疗反应方面的潜力。重要的是,[68Ga]Ga-RM2通过检测可改变整体分期和治疗策略的转移病灶,在改善和指导正确的治疗计划方面显示出了临床实用性。ER阳性BC的总体病灶检出率为93%(95% CI:87-98%)。与ER阴性病灶相比,ER阳性BC病灶的最大标准化摄取值(SUVmax)明显更高,加权平均差(WMD)为10.6(95% CI:8.1-13.2;P < 0.00001)。此外,与正常背景乳腺组织的 SUVmean 相比,ER 阳性 BC 病变的 SUVmax 具有显著的统计学意义,总体 WMD 为 9.9 (95% CI: 7.5-12.2; P < 0.00001)。应鼓励利用这种前景广阔的放射性示踪剂开展进一步研究,并在不久的将来实施前瞻性的大规模设计。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Seminars in nuclear medicine
Seminars in nuclear medicine 医学-核医学
CiteScore
9.80
自引率
6.10%
发文量
86
审稿时长
14 days
期刊介绍: Seminars in Nuclear Medicine is the leading review journal in nuclear medicine. Each issue brings you expert reviews and commentary on a single topic as selected by the Editors. The journal contains extensive coverage of the field of nuclear medicine, including PET, SPECT, and other molecular imaging studies, and related imaging studies. Full-color illustrations are used throughout to highlight important findings. Seminars is included in PubMed/Medline, Thomson/ISI, and other major scientific indexes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信